Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Genitourinary 1

Conditions

Melanoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Infliximab × Genitourinary × Clear all
NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡